Split intein-mediated protein trans-splicing to express large dystrophins.


Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
17 Jul 2024
Historique:
received: 09 05 2023
accepted: 12 06 2024
medline: 18 7 2024
pubmed: 18 7 2024
entrez: 17 7 2024
Statut: aheadofprint

Résumé

Gene replacement using adeno-associated virus (AAV) vectors is a promising therapeutic approach for many diseases

Identifiants

pubmed: 39020181
doi: 10.1038/s41586-024-07710-8
pii: 10.1038/s41586-024-07710-8
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Li, C. W. & Samulski, R. J. Engineering adeno-associated virus vectors for gene therapy. Nat. Rev. Genet. 21, 255–272 (2020).
pubmed: 32042148 doi: 10.1038/s41576-019-0205-4
Issa, S. S., Shaimardanova, A. A., Solovyeva, V. V. & Rizvanov, A. A. Various AAV serotypes and their applications in gene therapy: an overview. Cells 12, 785 (2023).
pubmed: 36899921 pmcid: 10000783 doi: 10.3390/cells12050785
Srivastava, A., Lusby, E. W. & Berns, K. I. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J. Virol. 45, 555–564 (1983).
pubmed: 6300419 pmcid: 256449 doi: 10.1128/jvi.45.2.555-564.1983
Weinmann, J. et al. Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants. Nat. Commun. 11, 5432 (2020).
pubmed: 33116134 pmcid: 7595228 doi: 10.1038/s41467-020-19230-w
Monaco, A. P. et al. Detection of deletions spanning the Duchenne muscular dystrophy locus using a tightly linked DNA segment. Nature 316, 842–845 (1985).
pubmed: 2993910 doi: 10.1038/316842a0
Kunkel, L. M. et al. Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature 322, 73–77 (1986).
pubmed: 3014348 doi: 10.1038/322073a0
Danialou, G. et al. Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. FASEB J. 15, 1655–1657 (2001).
pubmed: 11427517 doi: 10.1096/fj.01-0030fje
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M. & Sweeney, H. L. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl Acad. Sci. USA 90, 3710–3714 (1993).
pubmed: 8475120 pmcid: 46371 doi: 10.1073/pnas.90.8.3710
Ervasti, J. M. & Campbell, K. P. Membrane organization of the dystrophin-glycoprotein complex. Cell 66, 1121–1131 (1991).
pubmed: 1913804 doi: 10.1016/0092-8674(91)90035-W
Ervasti, J. M. & Campbell, K. P. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J. Cell Biol. 122, 809–823 (1993).
pubmed: 8349731 doi: 10.1083/jcb.122.4.809
Emery, A. E. H. The muscular dystrophies. Lancet 359, 687–695 (2002).
pubmed: 11879882 doi: 10.1016/S0140-6736(02)07815-7
Banks, G. B., Judge, L. M., Allen, J. M. & Chamberlain, J. S. The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins. PLoS Genet. 6, e1000958 (2010).
pubmed: 20502633 pmcid: 2873924 doi: 10.1371/journal.pgen.1000958
Gregorevic, P. et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat. Med. 12, 787–789 (2006).
pubmed: 16819550 pmcid: 4244883 doi: 10.1038/nm1439
Ramos, J. N. et al. Development of novel micro-dystrophins with enhanced functionality. Mol. Ther. 27, 623–635 (2019).
pubmed: 30718090 pmcid: 6403485 doi: 10.1016/j.ymthe.2019.01.002
Bostick, B. et al. AAV micro-dystrophin gene therapy alleviates stress-induced cardiac death but not myocardial fibrosis in >21-m-old mdx mice, an end-stage model of Duchenne muscular dystrophy cardiomyopathy. J. Mol. Cell. Cardiol. 53, 217–222 (2012).
pubmed: 22587991 pmcid: 3389274 doi: 10.1016/j.yjmcc.2012.05.002
Harper, S. Q. et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 8, 253–261 (2002).
pubmed: 11875496 doi: 10.1038/nm0302-253
Wasala, L. P. et al. The implication of hinge 1 and hinge 4 in micro-dystrophin gene therapy for Duchenne muscular dystrophy. Hum. Gene Ther. https://doi.org/10.1089/hum.2022.180 (2022).
Birch, S. M. et al. Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy. Sci. Transl. Med. 15, eabo1815 (2023).
pubmed: 36599002 pmcid: 11107748 doi: 10.1126/scitranslmed.abo1815
Koo, T., Popplewell, L., Athanasopoulos, T. & Dickson, G. Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice. Hum. Gene Ther. 25, 98–108 (2014).
pubmed: 24191945 doi: 10.1089/hum.2013.164
Lai, Y. et al. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat. Biotechnol. 23, 1435–1439 (2005).
pubmed: 16244658 pmcid: 2581721 doi: 10.1038/nbt1153
Lostal, W., Kodippili, K., Yue, Y. P. & Duan, D. S. Full-length dystrophin reconstitution with adeno-associated viral vectors. Hum. Gene Ther. 25, 552–562 (2014).
pubmed: 24580018 pmcid: 4064726 doi: 10.1089/hum.2013.210
Odom, G. L., Gregorevic, P., Allen, J. M. & Chamberlain, J. S. Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. Mol. Ther. 19, 36–45 (2011).
pubmed: 20859263 doi: 10.1038/mt.2010.205
Shah, N. H. & Muir, T. W. Inteins: nature’s gift to protein chemists. Chem. Sci. 5, 446–461 (2014).
pubmed: 24634716 doi: 10.1039/C3SC52951G
Esposito, F. et al. Liver gene therapy with intein-mediated F8 trans-splicing corrects mouse haemophilia A. EMBO Mol. Med. 14, e15199 (2022).
pubmed: 35491676 pmcid: 9174883 doi: 10.15252/emmm.202115199
Li, Y. F. Split-inteins and their bioapplications. Biotechnol. Lett 37, 2121–2137 (2015).
pubmed: 26153348 doi: 10.1007/s10529-015-1905-2
Padula, A. et al. Full-length ATP7B reconstituted through protein trans-splicing corrects Wilson disease in mice. Mol. Ther. Methods Clin. Dev. 26, 495–504 (2022).
pubmed: 36092366 pmcid: 9436707 doi: 10.1016/j.omtm.2022.08.004
Tornabene, P. et al. Inclusion of a degron reduces levels of undesired inteins after AAV-mediated protein trans-splicing in the retina. Mol. Ther. Methods Clin. Dev. 23, 448–459 (2021).
pubmed: 34786437 pmcid: 8571531 doi: 10.1016/j.omtm.2021.10.004
Tornabene, P. et al. Intein-mediated protein trans-splicing expands adeno-associated virus transfer capacity in the retina. Sci. Transl. Med. 11, eaav4523 (2019).
pubmed: 31092694 pmcid: 6863751 doi: 10.1126/scitranslmed.aav4523
Li, J., Sun, W. C., Wang, B., Xiao, X. & Liu, X. Q. Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy. Hum. Gene Ther. 19, 958–964 (2008).
pubmed: 18788906 pmcid: 2940629 doi: 10.1089/hum.2008.009
Carvajal-Vallejos, P., Pallissé, R., Mootz, H. D. & Schmidt, S. R. Unprecedented rates and efficiencies revealed for new natural split inteins from metagenomic sources. J. Biol. Chem. 287, 28686–28696 (2012).
pubmed: 22753413 pmcid: 3436554 doi: 10.1074/jbc.M112.372680
Caspi, J., Amitai, G., Belenkiy, O. & Pietrokovski, S. Distribution of split DnaE inteins in cyanobacteria. Mol. Microbiol. 50, 1569–1577 (2003).
pubmed: 14651639 pmcid: 7168405 doi: 10.1046/j.1365-2958.2003.03825.x
Shah, N. H., Dann, G. P., Vila-Perelló, M., Liu, Z. H. & Muir, T. W. Ultrafast protein splicing is common among cyanobacterial split inteins: implications for protein engineering. J. Am. Chem. Soc. 134, 11338–11341 (2012).
pubmed: 22734434 pmcid: 3535263 doi: 10.1021/ja303226x
Abedi, M. R., Caponigro, G. & Kamb, A. Green fluorescent protein as a scaffold for intracellular presentation of peptides. Nucleic Acids Res. 26, 623–630 (1998).
pubmed: 9421525 pmcid: 147301 doi: 10.1093/nar/26.2.623
Crudele, J. M. & Chamberlain, J. S. AAV-based gene therapies for the muscular dystrophies. Hum. Mol. Genet. 28, R102–R107 (2019).
pubmed: 31238336 pmcid: 6796995 doi: 10.1093/hmg/ddz128
Boer, J. M., de Meijer, E. J., Mank, E. M., van Ommen, G. B. & den Dunnen, J. T. Expression profiling in stably regenerating skeletal muscle of dystrophin-deficient mice. Neuromuscul. Disord. 12, S118–S124 (2002).
pubmed: 12206806 doi: 10.1016/S0960-8966(02)00092-5
Torres, L. F. B. & Duchen, L. W. The mutant mdx: inherited myopathy in the mouse. Morphological studies of nerves, muscles and end-plates. Brain 110, 269–299 (1987).
pubmed: 3567525 doi: 10.1093/brain/110.2.269
Bengtsson, N. E., Tasfaout, H., Hauschka, S. D. & Chamberlain, J. S. Dystrophin gene-editing stability is dependent on dystrophin levels in skeletal but not cardiac muscles. Mol. Ther. 29, 1070–1085 (2021).
pubmed: 33160075 doi: 10.1016/j.ymthe.2020.11.003
Lynch, G. S., Hinkle, R. T., Chamberlain, J. S., Brooks, S. V. & Faulkner, J. A. Force and power output of fast and slow skeletal muscles from mdx mice 6–28 months old. J. Physiol. 535, 591–600 (2001).
pubmed: 11533147 pmcid: 2278782 doi: 10.1111/j.1469-7793.2001.00591.x
Pastoret, C. & Sebille, A. Mdx mice show progressive weakness and muscle deterioration with age. J. Neurol. Sci. 129, 97–105 (1995).
pubmed: 7608742 doi: 10.1016/0022-510X(94)00276-T
Stedman, H. H. et al. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 352, 536–539 (1991).
pubmed: 1865908 doi: 10.1038/352536a0
Lefaucheur, J. P., Pastoret, C. & Sebille, A. Phenotype of dystrophinopathy in old mdx mice. Anat. Rec. 242, 70–76 (1995).
pubmed: 7604983 doi: 10.1002/ar.1092420109
Chamberlain, J. S., Metzger, J., Reyes, M., Townsend, D. W. & Faulkner, J. A. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J. 21, 2195–2204 (2007).
pubmed: 17360850 doi: 10.1096/fj.06-7353com
England, S. B. et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343, 180–182 (1990).
pubmed: 2404210 doi: 10.1038/343180a0
El Andari, J. et al. Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders. Sci. Adv. 8, eabn4704 (2022).
pubmed: 36129972 pmcid: 9491714 doi: 10.1126/sciadv.abn4704
Tabebordbar, M. et al. Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell 184, 4919–4938.e22 (2021).
pubmed: 34506722 pmcid: 9344975 doi: 10.1016/j.cell.2021.08.028
Hartigan-O’Connor, D., Kirk, C. J., Crawford, R., Mule, J. J. & Chamberlain, J. S. Immune evasion by muscle-specific gene expression in dystrophic muscle. Mol. Ther. 4, 525–533 (2001).
pubmed: 11735336 doi: 10.1006/mthe.2001.0496
Cordier, L. et al. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum. Gene Ther. 12, 205–215 (2001).
pubmed: 11177557 doi: 10.1089/104303401750061267
Boennemann, C. G. et al. Dystrophin immunity after gene therapy for Duchenne’s muscular dystrophy. N. Engl. J. Med. 388, 2294–2296 (2023).
doi: 10.1056/NEJMc2212912
Halbert, C. L., Allen, J. M. & Chamberlain, J. S. AAV6 vector production and purification for muscle gene therapy. Methods Mol. Biol. 1687, 257–266 (2018).
pubmed: 29067669 doi: 10.1007/978-1-4939-7374-3_18
Dellorusso, C., Crawford, R. W., Chamberlain, J. S. & Brooks, S. V. Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J. Muscle Res. Cell Motil. 22, 467–475 (2001).
pubmed: 11964072 doi: 10.1023/A:1014587918367
Gregorevic, P., Plant, D. R., Leeding, K. S., Bach, L. A. & Lynch, G. S. Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration. Am. J. Pathol. 161, 2263–2272 (2002).
pubmed: 12466140 pmcid: 1850914 doi: 10.1016/S0002-9440(10)64502-6
Kolwicz, S. C., Jr. & Tian, R. Assessment of cardiac function and energetics in isolated mouse hearts using 31P NMR spectroscopy. J. Vis. Exp. https://doi.org/10.3791/2069 (2010).
Kolwicz, S. C. Jr. et al. Gene therapy rescues cardiac dysfunction in Duchenne muscular dystrophy mice by elevating cardiomyocyte deoxy-adenosine triphosphate. JACC Basic Transl. Sci. 4, 778–791 (2019).
pubmed: 31998848 pmcid: 6978556 doi: 10.1016/j.jacbts.2019.06.006
Rafael, J. A. et al. Forced expression of dystrophin deletion constructs reveals structure-function correlations. J. Cell Biol. 134, 93–102 (1996).
pubmed: 8698825 doi: 10.1083/jcb.134.1.93

Auteurs

Hichem Tasfaout (H)

Department of Neurology, University of Washington School of Medicine, Seattle, WA, USA. tasfaout@uw.edu.
Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, University of Washington School of Medicine, Seattle, WA, USA. tasfaout@uw.edu.

Christine L Halbert (CL)

Department of Neurology, University of Washington School of Medicine, Seattle, WA, USA.
Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, University of Washington School of Medicine, Seattle, WA, USA.

Timothy S McMillen (TS)

Department of Bioengineering, College of Engineering and School of Medicine, University of Washington, Seattle, WA, USA.

James M Allen (JM)

Department of Neurology, University of Washington School of Medicine, Seattle, WA, USA.
Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, University of Washington School of Medicine, Seattle, WA, USA.

Theodore R Reyes (TR)

Department of Neurology, University of Washington School of Medicine, Seattle, WA, USA.
Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, University of Washington School of Medicine, Seattle, WA, USA.

Galina V Flint (GV)

Department of Bioengineering, College of Engineering and School of Medicine, University of Washington, Seattle, WA, USA.

Dirk Grimm (D)

Department of Infectious Diseases/Virology, Section Viral Vector Technologies, Medical Faculty and Faculty of Engineering Sciences, Center for Integrative Infectious Disease Research (CIID), University of Heidelberg, Heidelberg, Germany.
BioQuant, University of Heidelberg, Heidelberg, Germany.
German Center for Infection Research (DZIF) and German Center for Cardiovascular Research (DZHK), Heidelberg, Germany.

Stephen D Hauschka (SD)

Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, University of Washington School of Medicine, Seattle, WA, USA.
Department of Biochemistry, University of Washington School of Medicine, Seattle, WA, USA.

Michael Regnier (M)

Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, University of Washington School of Medicine, Seattle, WA, USA.
Department of Bioengineering, College of Engineering and School of Medicine, University of Washington, Seattle, WA, USA.
Center for Translational Muscle Research, University of Washington, Seattle, WA, USA.

Jeffrey S Chamberlain (JS)

Department of Neurology, University of Washington School of Medicine, Seattle, WA, USA. jsc5@uw.edu.
Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, University of Washington School of Medicine, Seattle, WA, USA. jsc5@uw.edu.
Department of Biochemistry, University of Washington School of Medicine, Seattle, WA, USA. jsc5@uw.edu.
Center for Translational Muscle Research, University of Washington, Seattle, WA, USA. jsc5@uw.edu.

Classifications MeSH